Weiss Asset Management’s Orchestra BioMed OBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-306,304
Closed -$3.05M 688
2022
Q2
$3.05M Buy
306,304
+10,000
+3% +$99.4K 0.07% 310
2022
Q1
$2.94M Hold
296,304
0.06% 371
2021
Q4
$2.96M Buy
296,304
+180,482
+156% +$1.78M 0.06% 378
2021
Q3
$1.15M Buy
+115,822
New +$1.14M 0.03% 365

Other funds holding OBIO

Weiss Asset Management's OBIO Position: Q3 2022 in Review

Weiss Asset Management sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 306,304 shares — an estimated $3.05M sold.

Weiss Asset Management first reported a position in OBIO in Q3 2021 and held it in 4 quarters. The position peaked at $3.05M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Weiss Asset Management reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Weiss Asset Management sold 306,304 Orchestra BioMed shares in Q3 2022, an estimated $3.05M.
  • Weiss Asset Management first reported a position in Orchestra BioMed in Q3 2021 and held it in 4 quarters.
  • Weiss Asset Management's Orchestra BioMed position peaked at $3.05M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Weiss Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.